Minoo, Japan

Naomi Hanioka


Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2002-2007

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Journey of Naomi Hanioka

Introduction

Naomi Hanioka, based in Minoo, Japan, is an accomplished inventor with a commendable portfolio of innovative patents. With a focus on pharmaceutical advancements, her work has made significant contributions to the field of medicine.

Latest Patents

Hanioka holds two patents, including her latest on propanolamine derivatives. This invention encompasses new propanolamine derivatives or their salts represented by a specific formula. The derivatives possess various health benefits, including gut selective sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic, anti-urinary incontinence, and anti-pollakiuria activities. Her research provides processes for their preparation, pharmaceutical compositions including these derivatives, and methods for the prevention and treatment of specified diseases in humans and animals.

Career Highlights

Throughout her career, Naomi has worked with prominent companies in the pharmaceutical industry, notably Fujisawa Pharmaceutical Company, Ltd. and Astellas Pharma GmbH. Her experience in these organizations has greatly enriched her expertise in drug development and innovation.

Collaborations

Hanioka's journey has also involved collaboration with respected colleagues in her field, including Kiyoshi Taniguchi and Minoru Sakurai. These partnerships have undoubtedly enhanced her work, allowing for greater contributions to scientific advancements.

Conclusion

Naomi Hanioka exemplifies the spirit of innovation in the pharmaceutical industry. Through her two patents and successful collaborations, she continues to pave the way for effective medical solutions. Her contributions reflect the ongoing importance of inventors in creating advancements that benefit public health.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…